Allocations
State Street is to work with Fidelity National Information Services (FIS) to distribute its GX Private Equity Index (PEI), a benchmark for comparative analysis of private equity performance, to nearly 300 global asset management clients, including private equity managers, investors and third-party administrators.
The PEI will be integrated into FIS’s Data Exchange portal (DX), a platform for sharing documents and data via advanced data visualisations, analytics and dynamic and interactive reporting.
“State Street’s GX Private Equity Index is a high-quality, industry-recognised source of private equity data,” says Sami Juma, chief operating officer, private equity business for Fidelity National. “We
LongueVue Capital (LVC), a New Orleans-based private equity firm, has held the final closing of LongueVue Capital Partners III (LVC III).
Building on LVC's predecessor funds, LVC III will focus on private equity investments in lower middle market companies across a variety of industries.
LongueVue Capital welcomed new institutional investors into the partnership, including The University of Texas Investment Management Company (UTIMCO).
In addition to the final closing, LVC received a Small Business Investment Company (SBIC) licensure of LVC III. The fund was oversubscribed and closed at its hard cap of USD252 million, including SBIC leverage.
LongueVue
Panasonic Corporation is to establish a new company, Panasonic Ventures, in April 2017, which will be based in California and invest in start-up companies mainly in the US, with initial investments of around USD100 million.
Panasonic has invested in Silicon Valley start-ups with cutting-edge technologies for nearly 20 years since 1998.
As a member of the venture community, the company has been helping these firms grow by providing a wide array of in-house technologies and human resources.
Going forward, Panasonic Ventures, with new external venture capitalists, will spearhead Panasonic's investments in start-ups that have unique business models or
Omnes Capital, with the support of co-investors Capital Transmission (Banque Cantonale de Genève) and Bpifrance, has acquired a stake in Groupe RGF alongside buyer Pascal Daviet as part of a management buy-in (MBI).
Joël Béraldin, director and 100 per cent shareholder in the company, has sold all of his shares and has acquired minority stakes in the new transaction.
Based in Pratz, the group specialises in the design and production of plastic and/or metal technical small parts in niche markets. Groupe RGF covers the entire production chain, including design, creation of moulds, injection, undercutting, overmoulding and automated assembly. The
CVC Capital Partners Fund VI has completed the acquisition of Corialis (Core Innovative Aluminium Integrated Solutions), a European manufacturer of aluminium profiles and systems, supplying door, window and conservatory manufacturers in both the new construction and refurbishment markets, from Advent International.
The transaction values Corialis at an enterprise value of approximately EUR1 billion.
Steven Buyse, partner at CVC Capital Partners, says: “We are delighted to partner with Johan and his talented leadership team to further build out this highly successful business. Consistently delivering high-quality aluminium profile systems with industry-leading lead times and service levels has led to a fantastic
Proveca, a European paediatric speciality pharmaceutical company, has raised GBP4 million to fund the commercial launch of Sialanar and the development and commercialisation of its paediatric product portfolio.
Sialanar is a treatment for chronic pathological drooling in children, launched in the UK by Proveca, to be followed by the rest of Europe.
The investment was led by Catapult Ventures, managers of the GM&C Life Sciences Fund, alongside Kreos Capital, a European provider of growth debt financing.
The investment comes soon after the EU-wide PUMA (Paediatric Use Marketing Authorisation) regulatory approval of Sialanar (glycopyrronium, oral solution) for the symptomatic
Softbank’s decision to choose a Jersey-based financial services company to administer its USD100 billion technology fund is expected to lead to more funds domiciling in the island.
The Softbank Vision Fund was launched in October 2016 with the aim of becoming the biggest investor in the technology industry over the next decade.
The decision to have the fund administered in Jersey has been described as a “game changer” in the selection of fund domiciles by several attendees at the Jersey Finance Annual Funds Conference in London last week.
Christopher Griffin, counsel at law firm Carey Olsen, says Softbank’s choice
Quilvest Private Equity, the private equity arm of the Quilvest group, and Antoine Henry, former head of Sage France, have acquired Eudonet, a publisher and integrator of CRM solutions, from its current founders (Christophe Morizot, Bertrand de La Villegeorges and Guillaume Bouillot) and additional shareholders NAXICAP Partners.
The acquisition will be made through an organised divestiture process. Financial terms have not been disclosed.
Eudonet is a publisher and integrator of generalist and verticalised CRM (Customer Relationship Management) solutions. Available in SaaS, Cloud and On Premise mode, Eudonet solutions are adapted to the needs of any type of structure: SMEs,
Middle-market private equity firm Genstar Capital has acquired Bracket, a scientifically-driven clinical trial technology and specialty services provider, from Parthenon Capital Partners.
Bracket offers solutions that help pharmaceutical and biotechnology companies, as well as contract research organisations, maximise clinical data integrity and ultimately improve outcomes with clinical trials.
Bracket has over 700 employees and delivers services in more than 90 countries to a diverse base of global customers, including 15 of the top 20 biopharma companies.
Jeff Kinell, chief executive officer of Bracket, says: "Bracket has built a strong reputation with its customers to help them increase efficiency
Tilak Healthcare, a start-up from the iBionext network developing medical video games for both the diagnosis and follow-up of chronic diseases, has secured funding of EUR2.5 million from iBionext Growth Fund.
The funds will help the company accelerate the development of its therapeutic mobile games, first targeting the ophthalmology field, with macular diseases.
The alliance of digital innovation and clinical expertise will allow Tilak Healthcare to offer screening and prevention solutions, thus leading to a better follow-up of many chronic diseases.
Edouard Gasser, CEO of Tilak Healthcare, says: “At Tilak we are proud to adapt the power of
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
